Correction: Non-genetic risk factors of miscarriage: a comprehensive umbrella review of systematic review and meta-analysis

Correction: Ashadi et al. Reproductive Health 22, 236 (2025)

https://doi.org/10.1186/s12978-025–02180-1

In this article [1], Tables 3 and 4 appeared incorrectly and have now been corrected in the original publication. For completeness and transparency, the correct versions are displayed below:

Table 3.

Characteristics of studies on miscarriage factors (< 28 weeks)

Author	Non-genetic factors	Number of primary studies	Number of cases/ controls	Summary effect size based on random model (95%CI)	PI 95%	P-value random	The largest study	I2	P-value Egger test	NOS
Diseases
[46]	Rheumatoid arthritis	6	-	1/32(1/21–1/43)	-	0/001	-	25/8%	-	10
[47]	Underweight	9	20,512 168,691	1/08(0/98–1/20)	-	0/170	-	54%	did not exist	7
[47]	Overweight	7	25,618 87,644	1/07(1/02–1/12)	-	0/010	-	41%	did not exist	7
[47]	Obesity	7	11,934 87,644	1/15(1/08–1/23)	-	0/0001	-	8%	did not exist	7
[47]	Obesity (Grade 1)	3	2314 23,233	1/08(0/97–1/20)	-	0/180	-	47%	did not exist	7
[47]	Obesity (Grade 2)	3	1242 2333	1/50(1/32–1/70)	-	0/0001	-	23%	did not exist	7
[48]	PCOs	3	295 275	2/86(1/64–4/98)	Including the null value	0/0001	3/00(1/39–6/46)	0%	0/123	9
Medicines and treatments
[49]	Inhaled corticosteroid-s (anti-inflammatory and immunosuppressive medication)	3	-	1/20(1/15–1/24)	0/46–2/13	0/0001	1/20(1/20–1/30)	0%	0/428	8
[49]	Systemic corticosteroids (anti-inflammatory and immunosuppressive drugs)	2	-	1/41(0/86–2/32)	It could not be calculated	0/163	1/70(1/10–2/50)	36/8%	It could not be calculated	8
[50]	Endocervical versus decidual polypectomy	2	64 92	0/26(0/04–1/58)	It could not be calculated	0/145	0/58(0/07–4/89)	18/4%	It could not be calculated	11
Behavioral factors
[51]	Smoking	50	-	1/22(1/16–1/29)	0/90–1/51	0/0001	1/13(1/05 0 1/22)	58/4%	0/010	9
[51]	Second-hand smoke	17	-	1/11(0/94–1/30)	0/51–1/88	0/192	1/01(0/80–1/27)	44/5%	0/262	9
[52]	pregnancy intention	2	-	1/54(1/78–3/03)	It could not be calculated	0/213	1/10(0/90–1/50)	90%	It could not be calculated	8

Table 4.

Characteristics of studies on miscarriage factors (definition of miscarriage is not mentioned in the study)

Author	Non-genetic factors	Number of primary studies	Number of cases/ controls	Summary effect size based on random model (95%CI)	PI 95%	P-value random	The largest study	I2	P-value Egger test	NOS
Chemical biomarkers
[53]	Gamma-aminobutyric acid analog	4	-	1/64(1/13–2/37)	0/07–4/76	0/0001	1/90(1/10–3/40)	0%	0/762	9
[54]	High serum β-human chorionic gonadotropin	4	2558 46,876	2/88(1/76–4/68)	0/042 − 7/08	0/0001	2/18(1/38–3/49)	11/4%	0/270	8
[55]	hyperhomocysteinemia	3	117 133	0/53(0/33–0/86)	Including the null value	0/010	0/55(0/31–0/99)	0%	0/949	7
[55]	Serum Vitamin B12 deficiency	2	100 102	3/00(1/70–5/28)	It could not be calculated	0/0001	2/55(1/43–4/61)	9/3%	It could not be calculated	7
[55]	Folic acid deficiency	4	683 1138	0/78(0/48–1/27)	0/009 − 5/23	0/322	1/06(0/88–1/28)	75%	0/250	7
[56]	Thyroid autoimmune antibodies	10	1426 11,194	4/29(2/22–8/27)	0/10–8/00	0/0001	6/11(3/96–9/38)	87/6%	0/264	7
Semiconductor agents
[57]	fabrication	6	-	1/26(1/03–1/55)	0/40–2/38	0/020	0/94(0/58–1/50)	6/9%	0/210	11
[57]	Photo-lithography work	6	-	1/37(1/10–1/71)	0/41–2/57	0/005	1/43(1/02 - 2/01)	0%	0/037	11
[57]	Ethylene glycol ether	4	-	1/42(0/94–2/16)	0/03–5/13	0/090	1/43(1/02–2/01)	53/5%	0/145	11
[57]	Fluoride exposure	2	-	1/19(0/73–1/95)	It could not be calculated	0/472	1/14(0/66–1/99)	0%	It could not be calculated	11
Environmental factors
[58]	Particulate matter PM2.5	5	-	1/21(1/02–1/42)	0/37–2/37	0/025	1/04(1/03–1/06)	98/9%	0/711	10
[58]	Particulate matter PM10	5	-	1/09(1/02–1/17)	0/67–1/56	0/010	1/02(0/99–1/06)	82/1%	0/011	10
[59]	Pesticides	13	192,426 232,214	1/41(1/10–1/80)	0/39–2/68	0/006	1/62(1/58–1/65)	81/8%	0/379	8
[60]	Perfluoro-decanoate	5	-	1/59(0/95–2/66)	0/04–5/09	0/076	1/10(0/81–1/53)	62/8%	0/360	9
[60]	Perfluoro-hexane sulfonate	5	-	1/03(0/96–1/11)	0/65–1/48	0/368	1/04(0/96–1/12)	0%	0/794	9
[60]	Perfluoro- nonanoate	5	-	1/45(0/72–2/90)	0/01–6/34	0/292	0/86(0/70–1/06)	91/5%	0/495	9
[60]	Perfluoro- Octanoate sulphonate	9	-	1/00(0/88–1/12)	0/54–1/60	0/999	0/95(0/87–1/04)	34/1%	0/086	9
[60]	Perfluoro- octane sulfonic acid	9	-	1/06(0/94–1/21)	0/55–1/69	0/317	0/99(0/94–1/05)	43/7%	0/283	9
[61]	Antineoplastic agents	9	-	1/56(1/16–2/09)	0/30–3/18	0/003	1/16(0/99–1/35)	78/2%	0/289	10
[62]	Exposure to dioxins in food	2	837 1065	1/04(0/79–1/37)	It could not be calculated	0/751	0/98(0/83–1/17)	23/9%	It could not be calculated	9
Microbial, infectious agents and vaccination
[63]	Helicobacter pylori	6	1159 4750	1/50(1/05–2/14)	0/18–3/58	0/06	0/92(0/42–2/02)	27/8%	0/764	10
[64]	Serum antibodies against Toxoplasma gondii	11	2207 1717	3/98(2/03–7/77)	0/15–7/24	0/0001	1/59(0/95–2/66)	32/1%	0/005	9
[65]	Toxoplasma gondii IgG antibody	19	4130 3159	2/21(1/54–3/18)	0/28–4/25	0/0001	0/94(0/77–1/15)	83/9%	0/006	10
[65]	Toxoplasma gondii IgM antibody	19	4077 2740	4/33(2/42–7/76)	0/19–7/42	0/0001	1/14(0/73–1/77)	71/3%	0/001	10
[66]	HIV infection	2	155 948	1/35(0/77– 2/35)	It could not be calculated	0/29	1/58(0/74–3/37)	0%	It could not be calculated	8
[67]	Oral cholera vaccine	2	2147 1107	1/54(0/78–3/03)	It could not be calculated	0/205	1/62(0/76–3/44)	0%	It could not be calculated	9
[68]	HPV Vaccine	7	52,503 3,280,744	0/98(0/85–1/13)	0/43–1/78	0/852	0/94(0/87–1/02)	68/1%	0/724	11
[69]	Neisseria gonorrhoeae	3	-	2/11(0/50–8/92)	-	0/307	0/86(0/56–1/33)	72/9%	0/075	10
[70]	HPV	3	124 386	0/99(0/37–2/64)	Including the null value	0/990	1/80(0/99–3/30)	66/1%	0/701	10
[71]	hepatitis B virus infection	2	-	1/09(0/51–2/29)	It could not be calculated	0/817	0/77(0/53–1/12)	79/1%	It could not be calculated	9
[72]	hepatitis E virus infection	3	274 309	1/71(0/79–3/69)	Including the null value	0/169	1/49(0/46–4/78)	1/3%	0/080	10
[73]	Genital mycoplasma	19	1584 2020	2/35(1/50–3/67)	0/19–4/83	0/0001	1/17(0/61–2/23)	69/7%	0/471	8
[74]	Vaginal bacteria	7	622 836	1/30(1/04–1/62)	0/37–2/53	0/019	1/04(0/91–1/19)	56/8%	0/104	10
[75]	Dengue infection	5	-	1/90(0/95–3/78)	0/02–6/33	0/067	0/78(0/29–2/11)	17/5%	0/244	9
Diseases
[76]	Thyroid Cancer	3	2373 9838	1/80(1/28–2/52)	0/0002–10/53	0/001	2/07(1/58–2/72)	32/9%	0/056	9
[77]	Breast Cancer	2	-	1/04(0/86–1/26)	It could not be calculated	0/696	1/05(0/86–1/27)	0%	It could not be calculated	9
[78]	Gestational diabetes	26	2166 24,032	3/01(2/38–3/82)	0/76–4/38	0/0001	4/32(2/95–6/32)	68/2%	0/572	11
[79]	Leiomyomas	5	1394 20,435	0/86(0/72–1/03)	0/28–1/97	0/107	0/83(0/63–1/08)	0%	0/128	10
[80]	Hodgkin lymphoma	2	-	0/78(0/55–1/10)	It could not be calculated	0/160	0/80(0/50–1/29)	0%	It could not be calculated	9
[81]	Non-Hodgkin lymphoma	2	-	0/94(0/62–1/43)	It could not be calculated	0/787	1/10(0/90–1/40)	55/3%	It could not be calculated	9
[82]	Psoriasis	4	-	1/62(0/99–2/63)	0/01–6/10	0/050	1/10(1/00– 1/20)	80/6%	0/193	9
[83]	Lyme disease	3	-	1/27(0/42–3/85)	Including the null value	0/668	2/14(0/50–9/09)	0%	0/147	10
[84]	Uterine artery embolization	3	244 253	0/86(0/72–1/03)	Including the null value	0/290	1/40(0/66–2/97)	0%	0/963	10
[85]	Uterine fibroids	15	-	4/51(2/80–7/26)	-	0/0001	-	51/3%	-	10
[86]	Primary biliary cholangitis	4	596 1058	1/26(1/01–1/57)	0/19–3/12	0/035	1/22(0/86–1/75)	0%	0/880	10
[87]	Familial Mediterranean fever	5	910 1030	0/94(0/71–1/24)	0/16–2/67	0/693	0/93(0/63–1/36)	89%	0/17	10
[88]	Sjögren’s syndrome	4	343 902	9/35(4/18–20/91)	0/007 − 16/47	0/0001	16/32(6/79–39/23)	0%	0/005	11
[89]	Hyperandrogenic	6	572 694	1/47(0/92–2/35)	0/09–4/20	0/100	1/23(0/75–2/01)	42/7%	0/230	10
[90]	Systemic lupus erythematosus	3	4397 8,788,494	4/64(3/02–7/28)	Including the null value	0/0001	4/85(4/26–5/51)	66%	0/944	10
[91]	Depression	2	-	1/88(1/50–2/35)	It could not be calculated	-	-	0%	It could not be calculated	10
[91]	Anxiety	2	-	1/25(1/11–1/40)	It could not be calculated	-	-	0%	It could not be calculated	10
[92]	Non-alcoholic fatty liver	2	1870 4614	1/15(1/02–1/30)	It could not be calculated	0/02	-	0%	It could not be calculated	9
[93]	Epilepsy	6	-	1/78(1/11–2/85)	-	-	-	78/6%	-	11
[94]	Nausea and vomiting during pregnancy	2	-	0/40(0/12–1/27)	It could not be calculated	0/122	0/66(0/46–0/99)	77/6%	It could not be calculated	6
[95]	Primary antiphospholipid syndrome	3	190 287	2/47(1/11–5/47)	Including the null value	0/025	2/58(1/40–4/74)	36/9%	0/679	8
[96]	History of recurrent miscarriage	2	595 989	6/37(3/83–10/57)	It could not be calculated	0/0001	5/54(3/17–9/69)	13/1%	It could not be calculated	8
[97]	Vaginal bleeding	8	-	4/30(2/00–9/00)	-	-	-	93%	-	11
[98]	Diabetes Mellitus	13	110,872 7,266,388	1/23(1/13–1/33)	0/8–1/65	0/0001	1/11(1/07–1/15)	82/6%	0/812	7
[98]	T1DM	7	4806 233,055	1/18(1/01–1/37)	0/51–2/01	0/030	1/11(1/00–1/23)	49/1%	0/846	7
[98]	T2DM	6	-	1/08(1/04–1/12)	0/79–1/38	0/0001	1/04(1/00–1/09)	28/9%	0/062	7
[98]	Insulin-resistant diabetes mellitus	3	27,484 263,731	1/43(1/22–1/68)	0/019–5/71	0/0001	1/26(1/22–1/31)	87/8%	0/890	7
[99]	Hyperthyroidism	4	163 5278	2/11(0/23–18/85)	Including the null value	0/501	0/22(0/05–0/89)	78/6%	0/709	10
[100]	Family history of miscarriage	2	338 3450	2/31(1/73–3/09)	It could not be calculated	0/0001	2/52(1/74–3/66)	0%	It could not be calculated	10
[101]	Celiac disease	7	7978 78,241	1/34(1/10–1/65)	0/43–2/45	0/004	1/05(0/98–1/13)	62/6%	0/006	10
Medicines and treatments
[102]	Itraconazole	3	536 929	1/43(0/37–5/45)	Including the null value	0/594	1/44(0/15–13/58)	0%	0/428	9
[103]	Pregravid OCP	4	23,295 76,441	0/62(0/41–0/96)	0/011–4/57	0/032	0/97(0/90–1/05)	92/4%	0/203	9
[104]	Ondansetron	13	188,200 3,936,991	0/52(0/31–0/89)	0/025–3/53	0/017	0/82(0/64–1/05)	92/1%	0/634	9
[105]	Preconcep-tion care for women with diabetes	11	869 1836	0/86(0/70–1/06)	-	-	-	-	-	11
[106]	Proton pump inhibitors	3	-	0/85(0/70–1/90)	-	-	-	0%	-	10
[107]	Nonsteroidal anti-inflammatory drug	11	-	1/19(0/92–1/54)	0/46–3/43	0/163	1/10(0/99–1/22)	91/6%	0/54	10
[108]	Levothyroxine in autoimmunity	5	-	0/12(0/07–0/19)	-	0/0001	-	62%	-	9
[109]	Treating Chronic Hepatitis B Infection	-	-	0/47(0/11–1/92)	-	0/290	-	31%	-	9
[110]	Benzodiazepines in the treatment of anxiety	5	-	1/85(1/42–2/42)	0/29–3/68	0/0001	1/40(1/26–1/57)	76/5%	0/174	10
[111]	Amino Acid Salicylic Acid in IBD	5	-	1/14(0/65–2/01)	-	0/738	-	-	-	8
[112]	Triptans in the treatment of migraine and cluster headaches	2	178 50,865	3/54(2/24–5/59)	It could not be calculated	0/0001	3/64(2/22–5/99)	0%	It could not be calculated	10
[113]	enoxaparin and aspirin verses aspirin for thromboembolism and thromboprophylaxis during pregnancy	2	-	0/53(0/12–2/23)	It could not be calculated	0/392	0/38(0/26– 0/56)	34%	It could not be calculated	10
[114]	Topical retinoids	3	430 945	1/01(0/63–1/62)	Including the null value	0/937	1/41(0/77–2/61)	7/7%	0/156	9
[115]	Antipsychotics	4	1306 2482	1/05(0/61–1/81)	0/007–6/03	0/856	0/81(0/59– 1/11)	70%	0/741	9
[76]	Radiotherapy for thyroid cancer	6	6078 7270	1/07(0/99–1/16)	0/69–1/50	0/065	1/07(0/98–1/16)	0%	0/304	9
[116]	Colchine in the treatment of familial Mediterranean fever	4	590 1575	0/64(0/45–0/92)	0/03–3/65	0/003	0/57(0/33–0/99)	0%	0/897	9
[117]	Hemodialysis	2	-	0/38(0/12–1/23)	It could not be calculated	-	-	0%	It could not be calculated	9
[118]	Infliximab versus adalimumab in inflammatory bowel disease patients	5	193 97	0/60(0/17–2/09)	0/00024–8/42	0/429	0/32(0/03–4/01)	0%	0/727	11
[119]	surgical therapies for inflammatory bowel disease	5	246 530	2/02(1/13–3/60)	0/05–5/68	0/016	1/20(0/54–2/67)	8/4%	0/317	10
[120]	Hyperthyroidism Treatment (Propylthiouracil vs. Methimazole)	4	1734 1654	0/89(0/71–1/12)	0/13–2/81	0/336	0/90(0/71–1/13)	0%	0/592	9
[121]	Amniocentesis	6	-	1/59(0/98–2/59)	-	0/06	-	-	-	10
[121]	Chorionic villus sampling	2	-	1/61(0/36–7/26)	It could not be calculated	0/50	-	-	It could not be calculated	10
[122]	Cervical cerclage	6	904 622	0/42(0/28–0/63)	-	0/0001	-	71%	-	10
[123]	Long-acting insulin compared to intermediate-acting basal insulin	2	-	1/26(0/85–1/87)	It could not be calculated	0/233	1/25(0/84–1/86)	0%	It could not be calculated	9
[124]	Insulin lispro vs. regular	3	-	0/76(0/19–3/02)	-	-	-	-	-	8
[125]	Laser treatment in monochorionic diamniotic twin pregnancies with twin-to-twin transfusion syndrome	4	-	1/56(1/28–1/91)	0/28–3/24	0/0001	1/44(1/05–2/00)	0%	0/355	10
[126]	Laparoscopy vs. laparotomy in removal of uterine adnexal mass	11	299 504	1/53(0/66–3/54)	0/03–5/25	0/311	1/75(0/33–1/15)	0%	0/153	9
[127]	Poor HbA1C control versus optimal control	4	-	3/23(1/64–6/36)	0/0089–8/99	0/001	5/44(2/23–12/45)	28/2%	0/713	8
[128]	Histamine H2 Blockers in the Treatment of Gastroesophageal Reflux	2	738 1575	0/62(0/36–1/05)	It could not be calculated	-	-	-	It could not be calculated	9
[129]	Metformin in the treatment of polycystic ovary syndrome	4	326 454	0/19(0/12–0/31)	0/003–4/19	0/001	0/23(0/11–0/48)	0%	0/365	8
[130]	Hydroxychloroquine in the treatment of autoimmune diseases	4	363 707	1/85(1/10–3/14)	0/02–6/33	0/021	2/29(1/13–4/65)	12/4	0/436	9
[131]	hysteroscopic septum resection	7	258 184	0/25(0/07–0/88)	Including the null value	0/03	1/67(0/94–2/97)	81%	0/007	9
[132]	Radiation therapy during childhood	2	648 1247	1/20(0/83–1/73)	It could not be calculated	0/335	1/44(0/99–2/09)	45/6%	It could not be calculated	10
Trace elements
[133]	Cadmium	8	361 398	7/95(2/23–28/33)	0/004–15/40	0/001	2/23(1/40–3/93)	93/8%	0/115	9
[133]	Lead	15	765 1218	14/04(4/95–39/76)	0/032–20/10	0/0001	2/33(1/53–3/52)	96%	0/001	9
[133]	Copper	14	655 2108	0/07(0/02–0/19)	0/0001–6/35	0/0001	0/63(0/39–1/01)	95/4%	0/011	9
[133]	Zinc	14	673 2000	0/14(0/04–0/51)	Including the null value	0/003	0/22(0/13–0/36)	96/9%	0/309	9
Behavioral and emotional factors
[134]	IUD removal	-	-	0/51(0/39–0/66)	-	0/0001	-	85%		8
[135]	cocaine use /drug free controls	2	-	5/32(0/22–125/9)	It could not be calculated	-	-	-	It could not be calculated	5
[135]	cocaine polydrug users /drug free controls	2	-	10/56(1/74–64/1)	It could not be calculated	-	-	-	It could not be calculated	5
[135]	cocaine polydrug users /polydrug no cocaine controls	2	-	3/50(0/64–19/2)	It could not be calculated	-	-	-	It could not be calculated	5
[136]	Adverse childhood experiences	3	-	1/82(1/47–2/85)	-	0/001	-	0%	did not exist	10
[137]	intimate partner violence	9	-	2/03(1/25–3/31)	-	-	-	-	-	9
[137]	Sexual violence in childhood	6	-	1/35(0/75–2/44)	-	-	-	-	-	9
[138]	Breastfeeding	3	595 1324	0/88(0/33–2/34)	Including the null value	0/805	0/46(0/22–0/95)	63/7%	0/281	10
[139]	Pregnancy interval 6 to 11 months	2	-	1/00(0/80–1/24)	It could not be calculated	-	-	0%	It could not be calculated	9
Menstrual disorders
[140]	Short menstrual cycle	3	-	1/86(1/10–3/14)	Including the null value	0/020	1/74(0/88–3/44)	0%	0/782	11
[140]	Long menstrual cycles	4	-	1/88(1/02–3/47)	0/008–7/32	0/042	0/99(0/53–1/85)	43%	0/050	11
Occupational factors
[141]	Rotating shifts vs. daily shifts	14	-	1/04(0/84–1/29)	0/34–2/15	0/664	0/82(0/68–0/99)	63/8%	0/534	11
[141]	Working more than 40 h	5	-	1/72(1/27–2/34)	0/25–3/62	0/0001	1/80(1/02–3/19)	0%	0/491	11
[141]	Working the night shift	12	-	1/23(1/03–1/46)	0/52–2/07	0/021	1/32(1/04–1/68)	33/2%	0/507	11
[142]	Anesthetic gases	16	11,623 33,146	1/26(0/98–1/63)	0/29–2/70	0/068	0/85(0/71–1/01)	88/4%	0/735	9
[142]	Chemotherapy agents	6	2529 4866	1/20(0/79–1/83)	0/10–3/62	0/371	1/31(0/75–2/28)	32/4%	0/138	9
[143]	Exposure to noise	5	-	1/07(0/99–1/16)	0/63–1/58	0/087	1/10(1/00–1/20)	28/4%	0/874	8
[144]	Hairdresser	7	5413 1173	1/28(1/11–1/47)	0/39–2/46	0/0001	1/31(1/07–1/60)	0%	0/312	8
Nutritional factors
[145]	Coffee consumption	4	1143 2460	2/76(1/64–4/64)	0/02–7/50	0/0001	3/98(2/55–6/21)	63/8%	0/655	9
[145]	Caffeine consumption	11	3341 10,202	2/38(1/76–3/23)	0/47–3/98	0/0001	2/21(1/53–3/19)	63%	0/110	9
[146]	Fruit consumption	3	-	0/46(0/24–0/87)	Including the null value	0/017	0/30(0/20–0/30)	86/7%	0/585	11
[146]	Vegetable consumption	3	-	0/58(0/45–0/75)	0/001–6/94	0/0001	0/60(0/40–0/80)	0%	0/535	11
[146]	Fruit and vegetable consumption	3	-	0/81(0/43–1/53)	Including the null value	0/530	0/49(0/36–0/66)	79/7%	0/154	11
[146]	Meat consumption	2	-	0/84(0/44–1/61)	It could not be calculated	0/608	1/10(0/90–1/30)	74/4%	It could not be calculated	11
[146]	Red meat consumption	3	-	0/99(0/84–1/18)	0/01–5/22	0/994	0/98(0/81–1/18)	0%	0/984	11
[146]	White meat consumption	2	-	0/80(0/64–0/99)	It could not be calculated	0/046	0/82(0/65–1/02)	0%	It could not be calculated	11
[146]	Seafood consumption	4	-	0/81(0/67–0/98)	0/15–2/48	0/036	0/86(0/71–1/03)	35/7%	0/736	11
[146]	Dairy consumption	5	-	0/65(0/51–0/82)	0/13–2/22	0/0001	0/60(0/50–0/80)	44/8%	0/426	11
[146]	Egg consumption	3	-	0/85(0/62–1/15)	0/0002–9/06	0/307	0/70(0/60–0/80)	79/7%	0/743	11
[146]	Fat and oil consumption	2	-	1/07(0/49–2/31)	It could not be calculated	0/858	0/73(0/54–0/99)	90/4%	It could not be calculated	11
[146]	Sugar consumption	2	-	2/36(0/37–14/88)	It could not be calculated	0/361	1/10(0/87–1/40)	78/8 5	It could not be calculated	11
[146]	Cereal consumption	2	-	0/70(0/44–1/09)	It could not be calculated	0/118	0/57(0/41–0/79)	63/5%	It could not be calculated	11
Serum platelets
[147]	Average platelet volume	18	2168 1985	1/38(0/61–3/15)	0/009–6/37	0/433	1/43(1/07–1/91)	97/1%	0/682	10
[147]	Platelet distribution width	13	2100 2611	6/42(2/50–16/11)	0/03–11/77	0/0001	1/40(1/10–1/76)	98/2%	0/978	10

The original article has been corrected.